STTR Phase II: High throughput aligned nanofiber multiwell plates for glioblastoma research

Award Information
Agency:
National Science Foundation
Branch
n/a
Amount:
$499,983.00
Award Year:
2012
Program:
STTR
Phase:
Phase II
Contract:
1152691
Award Id:
n/a
Agency Tracking Number:
1152691
Solicitation Year:
2012
Solicitation Topic Code:
MM
Solicitation Number:
n/a
Small Business Information
1275 Kinnear Road, Columbus, OH, 43212-1155
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
830384223
Principal Investigator:
Jed Johnson
(937) 631-3596
jed.johnson@nanofibersolutions.com
Business Contact:
Jed Johnson
(937) 631-3596
jed.johnson@nanofibersolutions.com
Research Institute:
Ohio State University
Mariano Viapiano
1739 N High Street
Columbus, OH, 43210-
(614) 688-4636
Nonprofit college or university
Abstract
This Small Business Technology Transfer Phase II project seeks to address the unmet need for high-throughput, cost effective tools to model the metastasis of brain cancer cells. The proposed Phase II work will achieve three key objectives necessary for broad adoption: 1) eliminating the use of adhesive during multiwell plate production, 2) implement FDA-approved sterilization procedures utilizing the Sterigenics gamma radiation facility, and 3) additional biological data providing both a head-to-head comparison of our products to those already on the market while also creating a market "pull" for the pharmaceutical application of this technology in clinical treatments of brain cancer. A supply of high-throughput cell culture migration assays will allow researchers to understand and treat cancer metastasis in ways never before possible. It is anticipated that a result of this project will be faster and more effective drug developments to treat brain cancer and other metastasizing cancers. Extension of this technology to other types of cancer and areas of tissue engineering is anticipated once production conditions are fully established. The broader impact/commercial potential of this project is that it will provide improved, more accurate models of glioma migration having better predictive power and higher translational potential. Current surgical procedures for malignant brain tumors cannot remove all of the cells associated with the primary tumor and these cancer cells migrate into the surrounding tissue where they evade both detection and current chemotherapies, leading to secondary tumor formation and nearly 100% patient mortality. A multi-well plate in vitro migration assays will enable pharmaceutical research identifying key factors regulating glioma cell migration, potentially helping devise a broad range of effective therapies and drugs against these devastating tumors. If this initial form of high-throughput motility assay is successful, it will provide an innovative tool appropriate for researchers from a large variety of backgrounds beyond both glioma treatments and cancer. Additionally, strong commercial potential exists as the cell/tissue culture supplies market is expected to reach $4.97 billion globally by 2012; this market includes the proposed consumable research tool.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government